Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
The initiative was announced at World Hypertension Congress, Chennai
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Experts urge early detection & better access to care
Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Subscribe To Our Newsletter & Stay Updated
